Monthly Triple-Drug Combo Lowers Immune Reactions in Leprosy
A study found that monthly rifampin-moxifloxacin-minocycline (RMM) therapy reduces the risk of type 1 immunologic reactions in leprosy patients compared to traditional multidrug therapy (MDT). The research involved 111 patients treated at a Miami clinic, revealing a significant difference in type 1 reaction rates between the two therapies. While RMM therapy showed promise, the authors noted the need for further studies to confirm its effectiveness due to limitations in sample size and study design.
- ▪Monthly RMM therapy was associated with a lower risk for type 1 immunologic reactions than MDT in leprosy patients.
- ▪Type 1 reactions occurred in 56% of patients receiving MDT, while RMM therapy significantly reduced this risk.
- ▪The study was conducted with 111 patients at a Miami HD clinic between October 2010 and November 2025.
Medscape files mainly under health. We currently carry 231 of its stories.
Story provenance
Source · retrieval · rights · ranking — open for full record
inspect →
Story provenance
Attribution is not the same as permission. This drawer separates discovery metadata, excerpts, WeSearch-generated summaries, reuse status, and whether the publisher receives the visit. Nothing here claims a legal grant the publisher has not made.
Record
| Original publisher | Medscape |
| Canonical URL | https://www.medscape.com/viewarticle/monthly-rifampin-moxifloxacin-minocycline-therapy-lowers-2026a1000ihx?src=rss |
| Publication time | Wed, 3 Jun 2026 11:05:00 EDT |
| Retrieval time | 2026-06-03T15:12:09.866Z |
| Last seen | 2026-06-03T15:12:09.866Z |
| Headline source | Publisher (no WeSearch rewrite) |
| Excerpt source | publisher body |
| Excerpt method | First ~120 words (~800 chars) of extracted publisher body, fair-use limited. |
| Summary | WeSearch · cerebras-chat (WeSearch summarizer) |
| Summary source text | contentText |
| Citation coverage | Summary is a WeSearch-generated derivative; primary citation is the original publisher URL. |
| Cluster | azohb6k4_jGq |
| Cluster logic | Grouped by semantic title/content similarity across sources within a rolling window. Same-publisher template collisions are excluded from coverage comparison. |
| Ranking reason | Story pages are not engagement-ranked. Hub feeds use recency, with optional source-diversified chronological ordering (cap consecutive stories per source). No personalized ranking. |
| Publisher visit | Yes — open original |
| Substitutes article? | No — link-out required for full text |
Rights status (four layers)
WeSearch handling by dimension
| Indexing | May the item be indexed (stored, ranked, made findable)? | Allowed |
| Snippet | May a short excerpt of the publisher's text be shown? | Allowed |
| AI summary | May WeSearch generate its own short summary of the article? | Limited |
| Retrieval / RAG | May the content be exposed for third-party retrieval-augmented generation? | Not asserted |
| Model training | May the content be used to train AI models? | Not asserted |
| Commercial reuse | May the content be reused commercially? | Not permitted |
Basis: Derived from the published RSS/Atom feed. Contact: [email protected]. Reviewed: 2026-07-24.
Opening excerpt (first ~120 words) tap to expand
TOPLINE:Monthly rifampin-moxifloxacin-minocycline (RMM) therapy was associated with a lower risk for type 1 immunologic reactions than multidrug therapy (MDT) in patients with leprosy (Hansen disease [HD]) in a study.METHODOLOGY:Researchers conducted a retrospective cohort study of 111 patients with biopsy- and polymerase chain reaction-confirmed HD treated at a Miami HD clinic between October 2010 and November 2025.The mean age of the patients was 52 years (range, 15-85 years); 62% were male; 40%-43% were Hispanic, 52%-56% were non-Hispanic, 9%-12% were Black or African American, and 84%-88% were White; 70% had multibacillary disease.Patients received either World Health Organization-recommended MDT (monthly rifampin and daily dapsone and clofazimine; n = 86, 77%), the global gold…
Excerpt limited to ~120 words for fair-use compliance. The full article is at Medscape.
Discussion
0 commentsMore from Medscape
